| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* McGill University Health Center, Montreal, Quebec, Canada;
Center Hospitalier de l’Université de Montreal, Montreal, Quebec, Canada;
Clinique Médical du Quartier Latin, Montreal, Quebec, Canada;
Clinique l’Actuel, Montreal, Quebec, Canada;
¶ Hôpital Ste. Justine, Montreal, Quebec, Canada;
|| University of Montreal, Montreal, Quebec, Canada; and
# University of British Columbia, Vancouver, British Columbia, Canada
Both the magnitude and breadth of HIV-specific immunity were evaluated longitudinally on samples collected from six subjects starting highly active antiretroviral therapy (HAART) preseroconversion (group 1), 11 recently infected subjects starting HAART postseroconversion (group 2), five subjects starting HAART in the second half of the first year of infection (group 3), and six persons starting treatment in the chronic phase of infection (group 4). HIV-specific immunity was measured by IFN-
ELISPOT, detecting the frequency of cells responding to a panel of HLA-restricted HIV-1 peptides. Intracellular cytokine staining was used to detect the frequency of HIV-1 Gag p55-specific CD4+ and CD8+ T cells in a subset of participants. The magnitude and breadth of HIV-specific responses persisted in all group 1 subjects and in 5 of 11 (45%) group 2 subjects. Both of these parameters declined in 6 of 11 (55%) group 2 and in all group 3 and 4 individuals. All persons who maintained detectable numbers of HIV-1 Gag p55-specific CD4+ and CD8+ T cells after starting HAART preserved the intensity and breadth of their HIV-specific effector response. Our results show that HIV-specific immunity can be preserved even if HAART is initiated beyond the acute phase of infection.
This article has been cited by other articles:
|
|
 |
|
  G. Alter, S. Rihn, H. Streeck, N. Teigen, A. Piechocka-Trocha, K. Moss, K. Cohen, A. Meier, F. Pereyra, B. Walker, et al. Ligand-Independent Exhaustion of Killer Immunoglobulin-Like Receptor-Positive CD8+ T Cells in Human Immunodeficiency Virus Type 1 Infection J. Virol., October 1, 2008; 82(19): 9668 - 9677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shin, S. D. Blackburn, J. N. Blattman, and E. J. Wherry Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection J. Exp. Med., April 16, 2007; 204(4): 941 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Cohen, S. Pouvelle-Moratille, X.-F. Wang, S. Farci, G. Munier, D. Charron, A. Menez, M. Busson, and B. Maillere Scanning the HIV Genome for CD4+ T Cell Epitopes Restricted to HLA-DP4, the Most Prevalent HLA Class II Molecule J. Immunol., May 1, 2006; 176(9): 5401 - 5408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Casazza, M. R. Betts, B. J. Hill, J. M. Brenchley, D. A. Price, D. C. Douek, and R. A. Koup Immunologic Pressure within Class I-Restricted Cognate Human Immunodeficiency Virus Epitopes during Highly Active Antiretroviral Therapy J. Virol., March 15, 2005; 79(6): 3653 - 3663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Wherry, D. L. Barber, S. M. Kaech, J. N. Blattman, and R. Ahmed Antigen-independent memory CD8 T cells do not develop during chronic viral infection PNAS, November 9, 2004; 101(45): 16004 - 16009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lichterfeld, D. E. Kaufmann, X. G. Yu, S. K. Mui, M. M. Addo, M. N. Johnston, D. Cohen, G. K. Robbins, E. Pae, G. Alter, et al. Loss of HIV-1-specific CD8+ T Cell Proliferation after Acute HIV-1 Infection and Restoration by Vaccine-induced HIV-1-specific CD4+ T Cells J. Exp. Med., September 20, 2004; 200(6): 701 - 712. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
